{"url_path":"/sec/plyx/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-056973-index.html","accession_number":"0001213900-26-056973","cik":"0002075320","ticker":"PLYX","issuer_name":"Polaryx Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-056973-index.html","primary_entity_key":"0002075320","primary_entity_name":"Polaryx Therapeutics, Inc."},"word_count":105,"has_tables":true,"body_markdown":"Item 1A. Risk Factors\n\n* *\n\nIn addition to the other information included\nin this report, you should carefully consider the discussion of risk factors affecting the Company as set forth in Part I, Item 1A “Risk\nFactors” included in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business,\nfinancial condition or future results. The risks described in these reports are not the only risks facing the Company. Additional risks\nand uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business,\nfinancial condition, and operating results."}